SEARCH:   Advanced

Blood, 15 March 2004, Vol. 103, No. 6, pp. 2003-2008. Prepublished online as a Blood First Edition Paper on November 26, 2003; DOI 10.1182/blood-2003-10-3616. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-10-3616v1 103/6/2003    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Boeckh, M. Articles by Nichols, W. G. Search for Related Content PubMed PubMed Citation Articles by Boeckh, M. Articles by Nichols, W. G. Related Collections Perspectives Neoplasia Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  PERSPECTIVES The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy Michael Boeckh, and W. Garrett Nichols From the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA. Abstract In the current era of effective prophylactic and preemptive therapy, cytomegalovirus (CMV) is now a rare cause of early mortality after hematopoietic stem cell transplantation (HSCT). However, the ultimate goal of completely eliminating the impact of CMV on survival remains elusive. Although the direct effects of CMV (ie, CMV pneumonia) have been largely eliminated, several recent cohort studies show that CMV-seropositive transplant recipients and seronegative recipients of a positive graft appear to have a persistent mortality disadvantage when compared with seronegative recipients with a seronegative donor. Recipients of T-cell–depleted allografts and/or transplants from unrelated or HLA-mismatched donors seem to be predominantly affected. Reasons likely include both incomplete prevention of direct and indirect or immunomodulatory effects of CMV as well as consequences of drug toxicities. The effect of donor CMV serostatus on outcome remains controversial. Large multicenter cohort studies are needed to better define the subgroups of seropositive patients that may benefit from intensified prevention strategies and to define the impact of CMV donor serostatus in the era of high-resolution HLA matching. Prevention strategies may require targeting both the direct and indirect effects of CMV infection by immunologic or antiviral drug strategies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Schub, I. G. Schuster, W. Hammerschmidt, and A. Moosmann CMV-Specific TCR-Transgenic T Cells for Immunotherapy J. Immunol., November 15, 2009; 183(10): 6819 - 6830. [Abstract] [Full Text] [PDF] W. Zhou, J. Longmate, S. F. Lacey, J. M. Palmer, G. Gallez-Hawkins, L. Thao, R. Spielberger, R. Nakamura, S. J. Forman, J. A. Zaia, et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients Blood, June 18, 2009; 113(25): 6465 - 6476. [Abstract] [Full Text] [PDF] M. Boeckh and P. Ljungman How we treat cytomegalovirus in hematopoietic cell transplant recipients Blood, June 4, 2009; 113(23): 5711 - 5719. [Abstract] [Full Text] [PDF] T. Crough and R. Khanna Immunobiology of Human Cytomegalovirus: from Bench to Bedside Clin. Microbiol. Rev., January 1, 2009; 22(1): 76 - 98. [Abstract] [Full Text] [PDF] D. J. Winston, J.-A. H. Young, V. Pullarkat, G. A. Papanicolaou, R. Vij, E. Vance, G. J. Alangaden, R. F. Chemaly, F. Petersen, N. Chao, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study Blood, June 1, 2008; 111(11): 5403 - 5410. [Abstract] [Full Text] [PDF] P. Bozidis, C. D. Williamson, and A. M. Colberg-Poley Mitochondrial and Secretory Human Cytomegalovirus UL37 Proteins Traffic into Mitochondrion-Associated Membranes of Human Cells J. Virol., March 15, 2008; 82(6): 2715 - 2726. [Abstract] [Full Text] [PDF] K. Klenovsek, F. Weisel, A. Schneider, U. Appelt, S. Jonjic, M. Messerle, B. Bradel-Tretheway, T. H. Winkler, and M. Mach Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells Blood, November 1, 2007; 110(9): 3472 - 3479. [Abstract] [Full Text] [PDF] A. Egli, S. Binggeli, S. Bodaghi, A. Dumoulin, G. A. Funk, N. Khanna, D. Leuenberger, R. Gosert, and H. H. Hirsch Cytomegalovirus and polyomavirus BK posttransplant Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_8): viii72 - viii82. [Abstract] [Full Text] [PDF] P. Ljungman and R. Brand Factors influencing CMV seropositivity in stem cell transplant patients and donors Haematologica, August 1, 2007; 92(8): 1139 - 1142. [Abstract] [Full Text] [PDF] F. M. Marty, J. Bryar, S. K. Browne, T. Schwarzberg, V. T. Ho, I. V. Bassett, J. Koreth, E. P. Alyea, R. J. Soiffer, C. S. Cutler, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis Blood, July 15, 2007; 110(2): 490 - 500. [Abstract] [Full Text] [PDF] M. S. Mavinakere, C. D. Williamson, V. S. Goldmacher, and A. M. Colberg-Poley Processing of Human Cytomegalovirus UL37 Mutant Glycoproteins in the Endoplasmic Reticulum Lumen prior to Mitochondrial Importation J. Virol., July 15, 2006; 80(14): 6771 - 6783. [Abstract] [Full Text] [PDF] J. C. Wade Viral Infections in Patients with Hematological Malignancies Hematology, January 1, 2006; 2006(1): 368 - 374. [Abstract] [Full Text] [PDF] Y. Chalandon, S. Degermann, J. Villard, L. Arlettaz, L. Kaiser, S. Vischer, S. Walter, M. H. M. Heemskerk, R. A. W. van Lier, C. Helg, et al. Pretransplantation CMV-specific T cells protect recipients of T-cell-depleted grafts against CMV-related complications Blood, January 1, 2006; 107(1): 389 - 396. [Abstract] [Full Text] [PDF] M. L. Sorror, M. B. Maris, B. M. Sandmaier, B. E. Storer, M. J. Stuart, U. Hegenbart, E. Agura, T. R. Chauncey, J. Leis, M. Pulsipher, et al. Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia J. Clin. Oncol., June 1, 2005; 23(16): 3819 - 3829. [Abstract] [Full Text] [PDF] R. R. Razonable Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients Am. J. Health Syst. Pharm., April 15, 2005; 62(suppl_1): S7 - S13. [Abstract] [Full Text] [PDF] M. Mazzucato, M. R. Cozzi, P. Pradella, Z. M. Ruggeri, and L. De Marco Distinct roles of ADP receptors in von Willebrand factor-mediated platelet signaling and activation under high flow Blood, November 15, 2004; 104(10): 3221 - 3227. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020